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In this issue of the Annals are three articles that describe
a substantial increase in the number of therapeutic mas-
tectomies for breast cancer and an increased rate of
contralateral prophylactic mastectomies.1–3 These publi-
cations reflect a national trend that is most likely the result
of multiple factors. Of these, the major influence is a
change in patient attitudes and their choices as they con-
template the benefits and risks of an increasing array of
surgical options for breast cancer. Simultaneously, they are
exposed to better information about future risks of con-
tralateral disease and the increasing trend to have bilateral
mastectomies to achieve a cancer treatment benefit, cancer
prevention, cosmetically better symmetry of their breasts,
and ‘‘peace of mind,’’ all in one surgical procedure.
However, these approaches are not for everyone, and it is
our burden of responsibility to ensure that patients are
properly informed about all their options and know the
relative risks and complications so they can be fully
informed as we ask them to participate in these complex
decisions.
The first of the three articles, by McGuire, Cox, and
colleagues from the H. Lee Moffitt Cancer Center and
University of South Florida in Tampa, describes a trend
that many of us have seen in our breast cancer practice, i.e.,
that the proportion of women undergoing total mastecto-
mies is on the rise.3 They have documented a striking
increase in total mastectomy (TM) rates at their institution
during a 13-year period (1994–2007) from an extensive
experience of 5,865 breast cancer patients. The rate of TM
increased from 33% in the initial 5-year period (1994–
1998) to 44% in the last 5-year period (2004–2007)
(p \ 0.01). More striking, during this last time frame, TM
rates increased from 35% in 2004 to a whopping 60% in
2007! This is a dramatic shift, for which the authors con-
cluded that ‘‘the tide is changing in regard to the surgical
management of breast cancer.’’ By logistic regression
analysis, the significant predictors of women choosing to
have a total mastectomy were: (1) age \40 years, (2)
increase in tumor size, and (3) presence of lymphovascular
invasion.
This trend occurred despite the fact that they helped
establish an advocacy group of breast cancer survivors,
which was formed for the purpose of educating women in
Florida about the relative benefits of breast conservation
treatment. Paradoxically, these efforts may have been one
reason women coming to their Breast Center were choos-
ing mastectomy after getting opinions from their peers. In
discussions with Dr. Cox, he is convinced that this change
is driven primarily by patient choice, because all of their
patients are considered for lumpectomy as well as total
mastectomy. Interestingly, this choice is not influenced as
much by a desire for immediate breast reconstruction, even
though reconstruction is discussed with all patients who
undergo total mastectomy. Their rate of immediate breast
reconstruction actually decreased during this time period,
from 16% in the initial 5-year period (1994–1998) to 7% in
the latest time period (2004–2007) (p \ 0.01).
During the past three decades, we have witnessed
advances in the surgical management through a series of
clinical trials comparing the Halsted radical mastectomy
with modified radical mastectomy in the 1970s to the
paradigm-changing surgical trials in the 1980s demon-
strating the survival equivalency of breast conservation
therapy (segmental mastectomy plus breast irradiation or
BCT) and total mastectomy. There was a lot of ‘‘persua-
sion’’ that BCT was actually a superior treatment, because
of the disfigurement and asymmetry of a total mastectomy,
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especially in women with larger breasts. Surgeons were
admonished to offer women BCT and some states even
passed legislation to ensure the public that BCT would be
offered to all women with breast cancer. In other words, the
transition to performing more BCT was made by encour-
aging surgeons ‘‘to give women a choice from among
treatment options.’’ Over time, surgeons responded and the
rate of BCT did increase and the vast majority of women in
the 1990s had BCT instead of total mastectomy. Indeed, a
standard for accreditation by the National Accreditation
Program for Breast Centers (NAPBC) is to demonstrate
that 50% of patients with early-stage breast cancer are
offered and/or treated with breast conservation surgery. But
what happens if the women in your referral area are
properly informed and still chose mastectomy over lump-
ectomy? We have all stated that ‘‘patients should have a
choice’’ and made a presumption that lumpectomy was
better. But in the absence of evidence that lumpectomy
provides a medically superior treatment outcome, we must
defer to the patients final decision when the choice between
lumpectomy and mastectomy is based on differing quality-
of-life perceptions and a varying risk-avoidance philosophy
by patients about local recurrence rates after BCT.
During the past 10–15 years, there have been a number
of influences that could have contributed to this increasing
trend. The first is the increasing use of skin-sparing mas-
tectomy along with immediate or delayed breast
reconstruction surgery.4 Second is a better understanding
of risk factors that can identify women at higher risk for in-
breast recurrences with breast conservation. Third, is the
clearer picture of the late effects of breast irradiation and
the continued incremental risk for developing a second
breast cancer over time. Fourth and finally, women are
increasingly proactive about their breast health and
knowledgeable about their disease as well as the treatment
options to consider from information they get from a net-
work of breast cancer survivors, books about breast cancer,
and the internet. In short, they better understand their role
in choosing from among an array of breast treatment
options and how each might differentially impact their
quality of life. Each of these changes has brought about a
‘‘sea change’’ of activity for which the trends of increased
mastectomy rates are driven largely by patient-driven
decision-making.
We also have watched the tide turn once again in our
breast oncology practice at the Johns Hopkins Avon
Foundation Breast Center. Most notably, the availability of
immediate breast reconstructive surgery has given women
the choice to achieve breast symmetry with BCT or total
mastectomy with breast reconstruction. This has been
achieved with the advent of skin-sparing mastectomies as
an essential component of immediate breast reconstruction,
and its use has increased nationally during the past decade.4
This approach has been shown with long-term follow-up to
be an oncologically safe operation, with local recurrence
rates that are the same or even less than previously reported
rates with prior total mastectomy approaches.5–7
Also, we have a better understanding of the natural
history of breast cancer with regard to predicting in-breast
failure rates with BCT and have better imaging tools to
discern multicentric/multifocal breast tumors. Finally,
public education and patient advocacy about breast cancer
has made impressive strides and women with breast cancer
come to the surgeon much more informed than they did
only a decade ago. Many have made their decision even
before seeing the surgeon. In other words, the change we
are experiencing today is no doubt driven more by
informed patients when there are choices among equivalent
surgical outcomes with regard to 10-year survival rates.
Isn’t that what we wanted all along? If survival rates are
equivalent and we are describing ‘‘personalized breast
cancer therapies’’ to the public, wouldn’t it be wrong to
impose BCT as the ‘‘preferred treatment’’ as perceived by
the physician?
The second and third articles describe the increasing
trends of contralateral prophylactic mastectomies (CPM) in
women with increased risk for opposite breast cancers. One
study by Jones and colleagues focused on 201 patients who
underwent CPM from among a total of 1,840 patients
treated at the Ohio State Arthur James Cancer Center who
had a total mastectomy for unilateral breast cancer.2 In
contrast to the experience at the Moffitt series, there was no
trend of increased rate of total mastectomy, but the rate of
CPM increased from 6.5% in 1999 to 16.1% in 2007. The
201 women who choose CPM were: (1) younger, (2) more
highly educated, (3) had a lower stage of breast cancer, and
(4) were more likely to have a family history of breast
cancer.2
Similar results are reported in this issue by Arrington
and colleagues from the University of Minnesota on 165
patients who had a total mastectomy plus contralateral
prophylactic mastectomy treated at six hospitals in their
healthcare system in the years 2006 and 2007.1 Of the 571
patients, 48% underwent breast-conserving surgery, 23%
underwent unilateral mastectomy, and 30% underwent
mastectomy and CPM. Among all total mastectomy
patients, 56% underwent CPM. Independent predictors of
increased CPM rates were: (1) young age (\40
vs. [55 years), (2) large tumor size ([5 cm vs. \2 cm),
(2) positive family history, (4) lobular histology, (5) mul-
ticentric disease, (6) presence of nodal metastases, and (7)
surgeon gender (female). Interestingly, all patients who had
BRCA testing, regardless of the results, underwent CPM.
Occult contralateral breast cancer was found in 5.5% of
patients and lobular carcinoma in situ (LCIS) or atypical
ductal hyperplasia in an additional 2.4%—rates similar to a
2670 C. M. Balch, L. K. Jacobs
previous study that found occult cancer in 5% of patients
who had CPM.16 Most patients (62.4%) who have CPM
also chose immediate breast reconstruction.1 These inves-
tigators had previously reported a national trend of
increased CPM rates using SEER data.8,9
The justification for CPM is primarily one of reducing
the risk of developing a second breast cancer, although it is
controversial whether overall survival rates actually
improve through preventative surgery. In another study,
contralateral breast cancer developed in only 0.5% of 1,072
women with CPM compared with a 2.7% incidence of
contralateral BC among a sample of 317 patients without
CPM after a follow-up of 5.7 years; notably, there also was
a decreased breast cancer mortality rate.10 In some cir-
cumstances, a contralateral mastectomy is considered to
achieve symmetry, especially in larger breasted women, for
whom a substantial reduction mammoplasty would other-
wise be required. Finally, the results from breast genetic
testing have demonstrated a high risk of contralateral breast
cancer in BRCA ? patients. The Society of Surgical
Oncology has published two position papers about the role
of preventative surgery in this genetically determined high-
risk group.11,12
Our ability to better understand the natural history of
breast cancer and the availability of improved imaging and
genetic testing has no doubt influenced this rate of
CPM.13,14 In addition, women are much better informed,
educated, and proactive about their breast health. The list
of factors associated with an increased rate of CPM reflects
these confluent factors: (1) younger age, (2) multicentric
tumors, lobular histology, LCIS, or extensive ductal car-
cinoma in situ in the ipsilateral breast, (3) BRCA ? genes
or genetic testing, (4) anxiety about cancer and desire to
reduce the cancer risk, or (5) plans for immediate breast
reconstruction.1,8,9,14–18 After 1 to 2 years of follow-up, the
majority of women who undergo CPM reported satisfaction
with their decision and experienced psychosocial out-
comes similar to breast cancer survivors without the
procedure.19–21
The goal of making the final decision about surgical
management of the breast cancer—in partnership with each
patient—is to maximize the long-term results with regards
to local disease control, symmetry of the breasts, cosmetic
appearance, and emotional state. We are achieving this
because many, if not most, women with breast cancer now
are evaluated by a multidisciplinary team of breast spe-
cialists and patient advocates/survivors in a dedicated
Breast Center. These women come prepared with a more
informed and empowered ability to participate in decision-
making with regard to their breast management. The
teamwork and coordination between the breast imaging
specialists, breast oncology surgeons, breast reconstruction
surgeons, and breast radiation oncologists also have
resulted in better staging and consistent patient recom-
mendations. Rather than being alarmed by this trend, we
should acknowledge that the rising incidence of total
mastectomy emanates from technological advances in our
care and patient-driven choices. To ensure that all women
have access to a range of surgical treatment options, we
should continue to make improvements in BCT outcomes
and availability of high-quality radiation therapy, espe-
cially in rural areas and inner cities. In addition, we need to
ensure that all women have access to educational material
that is evidence-based, understandable, and balanced.
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